Identification of some benzoxazepines as anticancer agents inducing cancer cell apoptosis

Papers of special note have been highlighted as: • of interest

References

• 1 American Cancer Society. Cancers facts and figures (2017). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.
  Google Scholar
• 2 Makin G, Hickman JA. Apoptosis and cancer chemotherapy. Cell Tissue Res. 301, 143–152 (2000).
  Medline CASGoogle Scholar
• 3 Zhao X, Gu J, Yin D, Chen X. Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer. Bioorg. Med. Chem. Lett. 14(18), 4767–4770 (2010).
  Google Scholar
• 4 Gómez-Vidal JA, Campos J, Marchal JA et al. Actual targets in cytodifferentiation cancer therapy. Curr. Top. Med. Chem. 4(2), 175–202 (2004).
  Medline CASGoogle Scholar
• 5 Plati J, Bucur O, Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J. Cell. Biochem. 104, 1124–1149 (2008).
  Medline CASGoogle Scholar
• 6 Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 27, 6194–6206 (2008).
  Medline CASGoogle Scholar
• 7 Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35(4), 495–516 (2007).
  Medline CASGoogle Scholar
• 8 Kamei K, Maeda N, Nomura K et al. Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: discovery of piclozotan. Bioorg. Med. Chem. 14, 1978–1992 (2006). • Describes the synthesis of starting materials 2–4.
  Medline CASGoogle Scholar
• 9 Kuribara H. Effects of SUN 8399, a potent and selective 5-HT1A agonist, on conflict behavior and ambulatory activity in mice: comparison with those of buspirone, tandospirone and diazepam. Jpn J. Pharmacol. 64, 273–280 (1994).
  Medline CASGoogle Scholar
• 10 Tani Y, Ogata A, Koyama M, Inoue T. Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in Parkinsonian rats. Eur. J. Pharmacol. 649, 218–223 (2010).
  Medline CASGoogle Scholar
• 11 Lowe EW Jr, Ferrebee A, Rodriguez AL, Conn J, Meiler J. 3D-QSAR CoMFA study of benzoxazepine derivatives as mGluR5 positive allosteric modulators. Bioorg. Med. Chem. Lett. 20, 5922–5924 (2010).
  Medline CASGoogle Scholar
• 12 Uto Y, Ueno Y, Kiyotsuka Y et al. Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,41-piperi- dine] analogs. Eur. J. Med. Chem. 46, 1892–1896 (2011).
  Medline CASGoogle Scholar
• 13 Khaleghi F, Din LB, Jantan I, Yaakob WA, Khalilzadeh A. A facile synthesis of novel 1,4-benzoxazepine-2-one derivatives. Tetrahedron Lett. 52, 7182–7184 (2011).
  CASGoogle Scholar
• 14 Khaleghi F, Jantan I, Din LB, Yaccob WA, Khalilzadeh MA, Bukhari SN. Immunomodulatory effects of 1-(6-hydroxy-2-isopropenyl-1-benzofuran-5-yl)-1-ethanone from Petasites hybridus and its synthesized benzoxazepine derivatives. J. Nat. Med. 68, 351–357 (2014).
  Medline CASGoogle Scholar
• 15 Prabhakar V, Babu KS, Ravindranath LK, Kumari MS, Latha J. Synthesis, characterization and biological evaluation of 1,5-benzoxazepine derivatives containing carbazole ring. Hetero. Lett. 5, 579–594 (2015).
  CASGoogle Scholar
• 16 Díaz-Gavilán M, Gómez-Vidal JA, Rodríguez-Serrano F et al. Anticancer activity of (1,2,3,5-tetrahydro-4,1-Benzoxazepine-3-yl)-pyrimidines and -purines against the MCF-7 cell line: preliminary cDNA microarray studies. Bioorg. Med. Chem. Lett. 18, 1457–1460 (2008).
  Medline CASGoogle Scholar
• 17 Caba O, Díaz-Gavilán M, Rodríguez-Serrano F et al. Anticancer activity and cDNA microarray studies of a (RS)-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]-6-chloro-9H-purine, and an acyclic (RS)-O,N-acetalic 6-chloro-7H-purine. Eur. J. Med. Chem. 46, 3802–3809 (2011).
  Medline CASGoogle Scholar
• 18 Campos JM, García-Rubiño ME, Mahfoudh N, Lozano-López C. Chapter 9. Enantiomerically pure substituted benzo-fused heterocycles – a new class of anti-breast cancer agents. In: A Concise Review of Molecular Pathology of Breast Cancer. Gunduz M (Ed.). Intech Open, London, UK, 203–224 (2015). • Reported apoptosis induction of compound III.
  Google Scholar
• 19 Salvatore RN, Yoon CH, Jung KW. Synthesis of secondary amines. Tetrahedron 57, 7785–7811 (2001). • Describes the synthesis of intermediates 7 and 8.
  CASGoogle Scholar
• 20 Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl Cancer Inst. 82, 1107–1112 (1990).
  Medline CASGoogle Scholar
• 21 Boyed MR, Padl KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Develop. Res. 34, 91–109 (1995).
  Google Scholar
• 22 Monks A, Scudiero D, Skehan P et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl Cancer Inst. 83, 757–766 (1991).
  Medline CASGoogle Scholar
• 23 Kamal A, Reddy TS, Polepalli S et al. Synthesis and biological evaluation of podophyllotoxin congeners as tubulin polymerization inhibitors. Bioorg. Med. Chem. 22, 5466–5475 (2014).
  Medline CASGoogle Scholar
• 24 Kumar CP, Reddy TS, Mainkar PS et al. Synthesis and biological evaluation of 5,10- dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one structural derivatives as anticancer and apoptosis inducing agents. Eur. J. Med. Chem. 108, 674–686 (2016).
  MedlineGoogle Scholar
• 25 Gurtu V, Kain SR, Zhang G. Fluorometric and colorimetric detection of caspase activity associated with apoptosis. Anal. Biochem. 251, 98–102 (1997).
  Medline CASGoogle Scholar
• 26 George RF. Facile synthesis of simple 2-oxindole-based compounds with promising antiproliferative activity. Future Med. Chem. 10(3), 269–282 (2018).
  CASGoogle Scholar